GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Gross Profit

Acticor Biotech (XPAR:ALACT) Gross Profit : €0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Gross Profit?

Acticor Biotech's gross profit for the six months ended in Jun. 2023 was €0.00 Mil. Acticor Biotech's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was €0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Acticor Biotech's gross profit for the six months ended in Jun. 2023 was €0.00 Mil. Acticor Biotech's Revenue for the six months ended in Jun. 2023 was €0.00 Mil. Therefore, Acticor Biotech's Gross Margin % for the quarter that ended in Jun. 2023 was N/A%.

Acticor Biotech had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Acticor Biotech Gross Profit Historical Data

The historical data trend for Acticor Biotech's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Gross Profit Chart

Acticor Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial 0.05 - - - -

Acticor Biotech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Acticor Biotech's Gross Profit

For the Biotechnology subindustry, Acticor Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acticor Biotech's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's Gross Profit distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's Gross Profit falls into.



Acticor Biotech Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Acticor Biotech's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Acticor Biotech's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Acticor Biotech's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Acticor Biotech  (XPAR:ALACT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Acticor Biotech had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Acticor Biotech Gross Profit Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Acticor Biotech (XPAR:ALACT) Business Description

Traded in Other Exchanges
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines